Primary Objective:
1. To determine whether rhG-CSF treatment will increase the frequency of donor-derived cells
contributing to repair of damaged epithelial/endothelial or solid organ-specific tissue
caused by graft-versus-host disease (GVHD) in patients who underwent sex-mismatched stem cell
transplantation.
Secondary Objective:
1. To determine whether rhG-CSF treatment can alleviate GVHD-induced damage to
epithelial/endothelial or solid organ-specific tissue.